Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Credit agrmnt [a]
Acq. announced
|
|
Tribute Pharmaceuticals Canada Inc. (TBUFF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/28/2015 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Asset Purchase Agreement, by and among Tribute Pharmaceuticals International Inc., Mutual Pharmaceutical Company, Inc. and Sun Pharmaceutical Industries, Inc",
"Asset Purchase Agreement, by and among Tribute Pharmaceuticals International Inc., Mutual Pharmaceutical Company, Inc. and Sun Pharmaceutical Industries, Inc",
"Agency Agreement, by and among Tribute Pharmaceuticals Canada Inc., Dundee Securities Ltd., KES 7 Capital Inc. and Bloom Burton & Co. Inc",
"Agency Agreement, by and among Tribute Pharmaceuticals Canada Inc., Dundee Securities Ltd., KES 7 Capital Inc. and Bloom Burton & Co. Inc",
"Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor® and Commercial Expansion into U.S. Market ● William Maichle Hired as President of U.S. Operations MILTON, ONTARIO - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor® and its related authorized generic from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. . Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable...",
"Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor® and Commercial Expansion into U.S. Market ● William Maichle Hired as President of U.S. Operations MILTON, ONTARIO - Tribute Pharmaceuticals Canada Inc. , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary, Tribute Pharmaceuticals International Inc., a Barbados corporation, has acquired the U.S. rights to Fibricor® and its related authorized generic from a wholly owned step-down subsidiary of Sun Pharmaceutical Industries Ltd. . Financial terms of the deal include the payment of US$10 million as follows: US$5 million on closing; US$2 million payable..." |
|
| 10/08/2014 |
8-K
| Acquisition/merger/asset purchase announced |
|
|